Want to see SE:KLAR full AI Analyst Report?
Top Page
Klaria Pharma Holding AB
(KLAR)
Select Model
Select Model
Rating:40Underperform
Price Target:
kr0.58
▼(-27.25% Downside)
Action:Downgraded
Date:09/07/26
Overall score reflects very weak financial performance (persistent losses, significant cash burn, and negative equity) as the primary drag, reinforced by bearish technicals with the stock trading below all major moving averages. Valuation provides limited support because earnings are negative and no dividend yield is available.
Positive Factors
Buccal film platform
Klaria’s buccal thin-film platform gives the company a defined technological focus within specialty pharmaceuticals. If the delivery approach demonstrates clinical and regulatory value, it could support multiple product programs and create a reusable foundation for future partnering or commercialization.
Negative Factors
Persistent losses
Klaria has not yet converted its development activities into a sustainable earnings model. Minimal trailing revenue alongside substantial recurring losses means operating scale remains far below the level needed to support the business, leaving future progress dependent on successful pipeline advancement and external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Buccal film platform
Klaria’s buccal thin-film platform gives the company a defined technological focus within specialty pharmaceuticals. If the delivery approach demonstrates clinical and regulatory value, it could support multiple product programs and create a reusable foundation for future partnering or commercialization.
Read all positive factors
Klaria Pharma Holding AB (KLAR) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr150.78M
Dividend YieldN/A
Average Volume (3M)1.04M
Price to Earnings (P/E)―
Beta (1Y)2.03
Revenue Growth-99.01%
EPS Growth38.00%
CountrySE
Employees4
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.17
Shares Outstanding245,976,150
10 Day Avg. Volume1,512,386
30 Day Avg. Volume1,042,553
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-31.79
Price to Sales (P/S)13.71
P/FCF Ratio-3.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr24.00M
Klaria Pharma Holding AB Business Overview & Revenue Model
Company Description
Klaria Pharma Holding AB (publ.) functions as a pharmaceutical enterprise, active both in Sweden and across global territories. Its current portfolio features Sumatriptan for migraine management and Midazolam for combating acute epileptic seizures...
How the Company Makes Money
Klaria Pharma Holding AB’s primary path to monetization is typical of early-stage/specialty pharma development companies: progressing product candidates and its drug-delivery platform toward partnering and/or commercialization. Key expected revenu...
Klaria Pharma Holding AB Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
22
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 116.00K | 9.00M | 2.25M | 8.45M | 5.87M | 6.11M |
| Gross Profit | 2.84M | -2.23M | 2.25M | 8.45M | 5.87M | -4.85M |
| EBITDA | -23.20M | -9.20M | -19.99M | -20.81M | -44.80M | -39.41M |
| Net Income | -38.73M | -38.90M | -47.75M | -35.78M | -63.77M | -53.53M |
Balance Sheet | ||||||
| Total Assets | 37.47M | 40.77M | 57.27M | 72.95M | 120.27M | 118.31M |
| Cash, Cash Equivalents and Short-Term Investments | 8.47M | 342.00K | 598.00K | 1.25M | 16.76M | 25.49M |
| Total Debt | 9.70M | 0.00 | 23.07M | 18.93M | 17.09M | 31.72M |
| Total Liabilities | 71.08M | 44.65M | 53.96M | 31.81M | 44.19M | 48.89M |
| Stockholders Equity | -33.62M | -3.88M | 3.31M | 41.13M | 76.08M | 69.41M |
Cash Flow | ||||||
| Free Cash Flow | -13.48M | -35.04M | -11.94M | -3.37M | -49.77M | -24.80M |
| Operating Cash Flow | -48.51M | -35.04M | -11.94M | -9.06M | -49.73M | -24.80M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -42.00K | 0.00 |
| Financing Cash Flow | 55.01M | 34.78M | 11.27M | -6.46M | 41.06M | 19.04M |
Klaria Pharma Holding AB Technical Analysis
Negative
0.80
Price Trends
0.85
Negative
0.85
Negative
0.83
Negative
Market Momentum
-0.05
Positive
27.05
Positive
4.27
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:KLAR, the sentiment is Negative. The current price of 0.8 is below the 20-day moving average (MA) of 0.92, below the 50-day MA of 0.85, and below the 200-day MA of 0.83, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 27.05 is Positive, neither overbought nor oversold. The STOCH value of 4.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:KLAR.
Klaria Pharma Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | kr254.30M | -2.63 | -97.06% | ― | 4.74% | 66.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr1.13B | 54.79 | 65.99% | ― | ― | ― | |
49 Neutral | kr201.11M | -4.07 | -13.41% | ― | -68.66% | -137.27% | |
48 Neutral | kr241.33M | -3.70 | -54.41% | ― | ― | 32.79% | |
48 Neutral | kr192.20M | -8.14 | -56.09% | ― | ― | 14.10% | |
40 Underperform | kr150.78M | -3.68 | 289.25% | ― | -99.01% | 38.00% |
* Healthcare Sector Average
SE:KLAR
Klaria Pharma Holding AB
0.61
-0.05
-7.12%
SE:ALZCUR
AlzeCure Pharma AB
8.18
5.37
191.00%
SE:XBRANE
Xbrane Biopharma AB
9.76
-23.84
-70.95%
SE:ISOFOL
Isofol Medical AB
0.75
-0.10
-11.41%
SE:ELIC
Elicera Therapeutics AB
2.88
-3.78
-56.78%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
1.71
-1.13
-39.73%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.